SAN FRANCISCO — Summer's definitive failure of Summit Therapeutics plc's former lead candidate, ezutromid, led to disappointments across the Duchenne muscular dystrophy (DMD) community. Now with its pivot to antibiotics complete, its team expects to have one of just two novel mechanisms in the field's phase III lineup next year with ridinilazole. (See BioWorld, June 28, 2018.)